Items where Author is "Chan, SYT"

Journal article

ABDEL-FATAH, T.M.A., THANGAVELU, P.U., REID, L.E., MCCART REED, A.E., SAUNUS, J.M., DUIJF, P.H.G., SIMPSON, P.T., LAKHANI, S.R., BALL, G.R., PONGOR, L., GYORFFY, B., MOSELEY, P.M., GREEN, A.R., POCKLEY, A.G., CALDAS, C., ELLIS, I.O. and CHAN, S.Y.T., 2020. Association of sperm-associated antigen 5 and treatment response in patients With estrogen receptor–positive breast cancer. JAMA Network Open, 3 (7): e209486. ISSN 2574-3805

ABDEL-FATAH, T.M.A., ALI, R., SADIQ, M., MOSELEY, P.M., MESQUITA, K.A., BALL, G., GREEN, A.R., RAKHA, E.A., CHAN, S.Y.T. and MADHUSUDAN, S., 2019. ERCC1 is a predictor of anthracycline resistance and taxane sensitivity in early stage or locally advanced breast cancers. Cancers, 11 (8): 1149. ISSN 2072-6694

FOULDS, G.A., VADAKEKOLATHU, J., ABDEL-FATAH, T.M.A., NAGARAJAN, D., REEDER, S., JOHNSON, C., HOOD, S., MOSELEY, P.M., CHAN, S.Y.T., POCKLEY, A.G., RUTELLA, S. and MCARDLE, S.E.B., 2018. Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Frontiers in Immunology, 9: 2028. ISSN 1664-3224

ABDEL-FATAH, T.M.A., REES, R.C., POCKLEY, A.G., MOSELEY, P., BALL, G.R., CHAN, S.Y.T., ELLIS, I.O. and MILES, A.K., 2017. The localisation of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. Oncotarget, 8, pp. 112245-112257. ISSN 1949-2553

ABDEL-FATAH, T.M.A., AGARWAL, D., LIU, D.X., RUSSELL, R., RUEDA, O.M., LIU, K., XU, B., MOSELEY, P.M., GREEN, A.R., POCKLEY, A.G., REES, R.C., CALDAS, C., ELLIS, I.O., BALL, G.R. and CHAN, S.Y.T., 2016. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. The Lancet Oncology, 17 (7), pp. 1004-1018. ISSN 1470-2045

ABDEL-FATAH, T.M.A., MCARDLE, S.E., AGARWAL, D., MOSELEY, P.M., GREEN, A.R., BALL, G.R., POCKLEY, A.G., ELLIS, I.O., REES, R.C. and CHAN, S.Y.T., 2016. HAGE in triple negative breast cancer (TNBC) is a novel prognostic, predictive and actionable biomarker: a transcriptomic and protein expression analysis. Clinical Cancer Research, 22 (4), pp. 905-914. ISSN 1078-0432

ARORA, A., ABDEL-FATAH, T.M.A., AGARWAL, D., DOHERTY, R., CROTEAU, D.L., MOSELEY, P.M., HAMEED, K., GREEN, A., ALESKANDARANY, M.A., RAKHA, E.A., PATTERSON, K., BALL, G., CHAN, S.Y.T., ELLIS, I.O., BOHR, V.A., BRYANT, H.E. and MADHUSUDAN, S., 2016. Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. Carcinogenesis, 37 (1), pp. 63-71. ISSN 0143-3334

ABDEL-FATAH, T.M., BALL, G., LEE, A.H.S., PINDER, S., MACMILAN, R.D., CORNFORD, E., MOSELEY, P.M., SILVERMAN, R., PRICE, J., LATHAM, B., PALMER, D., CHAN, A., ELLIS, I.O. and CHAN, S.Y.T., 2015. Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer. Clinical Cancer Research, 21 (5), pp. 1052-1062. ISSN 1078-0432

ARORA, A., ABDEL-FATAH, T.M.A., AGARWAL, D., DOHERTY, R., MOSELEY, P.M., ALESKANDARANY, M.A., GREEN, A.R., BALL, G., ALSHAREEDA, A.T., RAKHA, E.A., CHAN, S.Y.T., ELLIS, I.O. and MADHUSUDAN, S., 2015. Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. Molecular Cancer Therapeutics, 14 (4), pp. 1057-1065. ISSN 1535-7163

ABDEL-FATAH, T.M.A., MCARDLE, S.E.B., JOHNSON, C., MOSELEY, P.M., BALL, G.R., POCKLEY, A.G., ELLIS, I.O., REES, R.C. and CHAN, S.Y.T., 2014. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer. British Journal of Cancer, 110 (10), pp. 2450-2461. ISSN 1532-1827

ABDEL-FATAH, T.M.A., PERRY, C., DICKINSON, P., BALL, G., MOSELEY, P., MADHUSUDAN, S., ELLIS, I.O. and CHAN, S.Y.T., 2013. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Annals of Oncology, 24 (11), pp. 2801-2807. ISSN 1569-8041